Percutaneous

Hoag Clinical Trial Contributes to 'Eye-Popping' National Heart Surgery Data

Retrieved on: 
월요일, 3월 18, 2019
Healthcare in California, Hoag, Percutaneous, Percutaneous aortic valve replacement

Hoag contributed to what the ACC referred to as "eye-popping" data at its annual meeting in New Orleans.

Key Points: 
  • Hoag contributed to what the ACC referred to as "eye-popping" data at its annual meeting in New Orleans.
  • As part of the PARTNER 3 trial, the Hoag TAVR team participated in research that included 1,000 low-surgical-risk patients.
  • Hoag became a site for the PARTNER 3 trial in 2016 and is a leader in performing these procedures.
  • In 2012, Hoag began offering TAVR, an innovative percutaneous procedure that offered hope to individuals at high risk for surgery.

Corindus Vascular Robotics Announces Closing of Private Placement for $15 Million

Retrieved on: 
화요일, 2월 26, 2019
Surgery, Technology, Other Technology, Health, Medical devices, U.S. Securities and Exchange Commission, Initial public offering, Prospectus, Percutaneous, Registration statement, Interventional cardiology, SEC filings

Corindus has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the private placement within 90 days of the closing of the private placement.

Key Points: 
  • Corindus has agreed to file a registration statement with the SEC covering the resale of the shares of common stock sold in the private placement within 90 days of the closing of the private placement.
  • Any resale of Corindus securities under such resale registration statement will be made only by means of a prospectus.
  • Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions.
  • The Companys CorPath platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures.

Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

Retrieved on: 
목요일, 2월 14, 2019
Technology, Other Technology, Health, Clinical trials, Medical devices, FDA, Medicine, Interventional cardiology, Percutaneous coronary intervention, Percutaneous, PCI, Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. (Corindus or theCompany) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention.

Key Points: 
  • Corindus Vascular Robotics, Inc. (Corindus or theCompany) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today it is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention.
  • CorPath GRX, the second generation robotic platform, received FDA clearance for percutaneous coronary intervention (PCI) in 2016 and peripheral vascular intervention (PVI) in 2018.
  • Upon successful FDA clearance, CorPath GRX would become the worlds first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).
  • The Companys CorPath platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures.

Contego Medical Receives 510(k) Clearance for the Paladin Carotid PTA Balloon System with Integrated Embolic Protection

Retrieved on: 
화요일, 9월 18, 2018
Interventional radiology, Angioplasty, Percutaneous

RALEIGH, N.C., Sept. 18, 2018 /PRNewswire/ --Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first filter-based Integrated Embolic Protection (IEP) device, the Paladin Carotid PTABalloon System.

Key Points: 
  • RALEIGH, N.C., Sept. 18, 2018 /PRNewswire/ --Contego Medical announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first filter-based Integrated Embolic Protection (IEP) device, the Paladin Carotid PTABalloon System.
  • The Paladin Carotid PTA Balloon System with Integrated Embolic Protection contains an angioplasty balloon and integrated 40-micron filter, coupled together for the first time.
  • "The Paladin System utilizes our patented Integrated Embolic Protection (IEP) technology, aimed atproviding superior performance while improving the safety profile ofexistingcardiovascular procedures.
  • The Paladin System with Integrated Embolic Protection (IEP), is indicated for Percutaneous Transluminal Angioplasty (PTA) in the carotid arteries with capture and removal of embolic material.

XACT Robotics Receives CE Mark for Its Robotics Navigation System for Percutaneous Procedures

Retrieved on: 
목요일, 9월 13, 2018
XACT, Percutaneous, Robotics

CAESAREA, Israel, Sept. 13, 2018 /PRNewswire/ -- XACT Robotics , a pioneer in robotic navigation and steering solutions for percutaneous image-guided procedures, announced today that it has received CE Mark approval for its robotics navigation and steering system for image-guided percutaneous procedures, such as ablations and biopsies.

Key Points: 
  • CAESAREA, Israel, Sept. 13, 2018 /PRNewswire/ -- XACT Robotics , a pioneer in robotic navigation and steering solutions for percutaneous image-guided procedures, announced today that it has received CE Mark approval for its robotics navigation and steering system for image-guided percutaneous procedures, such as ablations and biopsies.
  • The XACT robotics system is currently approved and being used for CT-guided percutaneous procedures in the abdomen.
  • The CE approved XACT system, which is the only robotics system to integrate robotic navigation with steering capabilities, can be used to accurately access any target in the abdomen in CT-guided percutaneous procedures.
  • Founded in 2013, XACT Robotics is a pioneer in robotic navigation and steering solutions for percutaneous image-guided procedures.

Essential Medical Announces Positive Results From the SAFE MANTA Clinical Trial, the First Pivotal Trial for a Dedicated Large Bore Closure Device

Retrieved on: 
월요일, 6월 25, 2018
Interventional cardiology, Interventional radiology, Vascular closure device, Percutaneous, Medicine

Essential Medical, Inc. , a private medical device company focused on innovative solutions for large bore vascular closure, today announced the results from the SAFE MANTA IDE clinical trial, the first pivotal trial for a dedicated large bore closure device.

Key Points: 
  • Essential Medical, Inc. , a private medical device company focused on innovative solutions for large bore vascular closure, today announced the results from the SAFE MANTA IDE clinical trial, the first pivotal trial for a dedicated large bore closure device.
  • The 14F MANTA device was used in 42 cases (16%) and the 18F device was used in 221 cases (84%).
  • Essential Medical is a privately held medical device company dedicated to improving patient outcomes with a large bore closure device that achieves fast, reliable closure with rapid hemostasis for cardiovascular procedures requiring percutaneous transcatheter interventions.
  • By fulfilling the unmet need for simple yet effective large bore closure, Essential Medical is mastering closure to support and enable growth of the fastest growing interventional segments within the cardiology market.

5EU Surgical Cardiovascular and Peripheral Vascular Procedures Volumes to 2021

Retrieved on: 
화요일, 6월 12, 2018
Medicine, Clinical medicine, Health care, Interventional radiology, Medical devices, Angioplasty, Vascular surgery, Percutaneous, Peripheral artery disease, Stent, Interventional cardiology, Surgery

The "5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures" report has been added to ResearchAndMarkets.com's offering.
  • This report presents procedure volumes forecasts for some of the most common cardiovascular and peripheral vascular surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU).
  • This report also presents an overview of the etiology and epidemiology of selected cardiovascular and peripheral vascular diseases/disorders, prevailing surgical approaches/techniques, and evolving procedural utilization trends.
  • Peripheral vascular interventional/surgical procedures covered include femoropopliteal bypass and stenting, percutaneous transluminal angioplasty, and stent grafting.

Peripheral Guidewires - Cardiovascular Market Analysis and Forecast Model

Retrieved on: 
월요일, 6월 4, 2018
Medicine, Interventional radiology, Health care, Clinical medicine, Angioplasty, Percutaneous, Stent, Catheter, Balloon catheter, Angiography, Cordis

Peripheral Guidewires - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Peripheral Guidewires within the Cardiovascular Devices market.

Key Points: 
  • Peripheral Guidewires - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Peripheral Guidewires within the Cardiovascular Devices market.
  • Peripheral Guidewires are used during percutaneous transluminal angioplasty (PTA) for guiding stents or balloon catheters to the site of blockage in the peripheral vasculature.
  • The Peripheral Guidewires Market is segmented into Hydrophilic Peripheral Guidewires and Non-Hydrophilic Peripheral Guidewires.
  • - Annualized total Peripheral Guidewires market revenue by segment and market outlooks from 2005-2024.

Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters - Cardiovascular Market Analysis and Forecast Model

Retrieved on: 
월요일, 6월 4, 2018
Medicine, Clinical medicine, Percutaneous coronary intervention, PTCA, Angioplasty, Interventional cardiology, Percutaneous, Johnson & Johnson, Balloon catheter, Cordis, Drug-eluting stent

Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters within the Cardiovascular Devices market.

Key Points: 
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters within the Cardiovascular Devices market.
  • - Currently marketed Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters and evolving competitive landscape.
  • - Annualized total Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters market revenue by segment and market outlooks from 2005-2024.
  • - Develop business strategies by understanding the trends shaping and driving the Percutaneous Transluminal Coronary Angioplasty (PTCA) Drug Eluting Balloon Catheters market.

Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters - Cardiovascular Market Analysis and Forecast Model

Retrieved on: 
월요일, 6월 4, 2018
Medicine, Clinical medicine, Interventional radiology, Angioplasty, Percutaneous, Balloon catheter, Catheter, PTA, Cordis, Percutaneous coronary intervention

Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters within the Cardiovascular Devices market.

Key Points: 
  • Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters - Cardiovascular Market Analysis and Forecast Model is built to better visualize quantitative market trends of Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters within the Cardiovascular Devices market.
  • - Annualized total Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters market revenue by segment and market outlooks from 2005-2024.
  • - Develop business strategies by understanding the trends shaping and driving the Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters market.
  • - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters market in the future.